Dosing & Research Reference
A structured reference to published clinical protocols, experimental research, commonly reported schedules, and formulation considerations for selected peptides and related compounds.
01. Retatrutide (LY3437943)— Research, dosing evidence, and safety
Overview
Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors. Clinical research has investigated its effects on body weight and metabolic outcomes.
Clinical-Trial Dosing Reference
| Trial Group | Target Dose | Frequency | Escalation |
|---|---|---|---|
| Lower-dose group | 2 mg | Once or twice a week | Trial-specific protocol |
| Intermediate-dose group | 5 mg | Once or tiwce a week | Gradual escalation in the trial |
| Intermediate-dose group | 8 mg | Once or twice a week | Gradual escalation in the trial |
| Higher-dose group | 12 mg | Once or twice a week | Gradual escalation in the trial |
Important: These entries identify target-dose groups studied in clinical research. The starting dose and escalation schedule varied by trial arm. A target dose is not necessarily the starting dose. Milligrams (mg) describe the amount of drug, not its concentration in a vial or the volume to administer.
Research and practical considerations
- Clinical-trial outcomes included substantial average weight reduction.
- Gastrointestinal adverse events were common and dose-related.
- Heart-rate changes were also observed in clinical research.
- Vial size alone does not establish drug concentration or an appropriate dose.
- Flu-like symptoms, including fatigue, chills, and body aches, may occur. Reduce the dose and hold off on increasing it until symptoms improve.
References
02. AOD-9604 — Research, dosing evidence, and safety
Overview
AOD-9604 is a modified fragment of human growth hormone investigated primarily in obesity and fat-metabolism research.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 2 mg | 300–500 mcg | Daily (as listed in source) |
| 5 mg | 300–500 mcg | Daily (as listed in source) |
| 10 mg | 300–500 mcg | Daily (as listed in source) |
The amounts above reproduce the entries in the supplied dosing chart; they are not independently validated clinical dosing recommendations. Vial strength represents the total amount in the vial, not the amount per administration. The chart does not establish a validated injectable regimen or an appropriate dose for an individual.
Research Considerations
- Route of administration and formulation matter when comparing studies.
- Online dosing tables should not be treated as equivalent to published clinical protocols.
- Claims about exercise timing and fat-burning effects require supporting clinical evidence.
- Research findings should be interpreted in the context of the original study.
References
03. Tesamorelin (TH9507)— Research, dosing evidence, and safety
Overview
Tesamorelin (TH9507) is a growth-hormone-releasing factor analogue investigated for its effects on growth-hormone signaling and visceral abdominal fat.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 5 mg | 2 mg | Daily (as listed in source) |
| 10 mg | 2 mg | Daily (as listed in source) |
| 20 mg | 2 mg | Daily (as listed in source) |
Vial strength represents the total amount in the vial, while the source-listed amount represents a separate quantity. These chart entries are not interchangeable with formulation-specific prescribing instructions.
Research Considerations
- Tesamorelin stimulates growth-hormone and IGF-1 signaling.
- Clinical research has evaluated visceral abdominal fat and metabolic outcomes.
- Glucose regulation, IGF-1 levels, fluid retention, and injection-site reactions are relevant monitoring topics.
References
04. CJC-1295 with DAC (DAC:GRF) — Research, dosing evidence, and safety
Overview
CJC-1295 with DAC (DAC:GRF) is a long-acting growth-hormone-releasing hormone analogue. The drug-affinity complex extends exposure and distinguishes it from short-acting products marketed as CJC-1295 without DAC.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 2 mg | 2 mg | Weekly (as listed in source) |
| 5 mg | 300 mcg–1 mg | Weekly (as listed in source) |
Published Human Research
| Research Feature | Study Description |
|---|---|
| Participants | Healthy adult volunteers |
| Administration | Single ascending doses and repeated weekly or biweekly dosing |
| Measures | Growth hormone, IGF-1, pharmacokinetics, and tolerability |
The foundational clinical study evaluated weight-based research doses, including 30 and 60 micrograms/kg. Those study doses are separate from the source-listed entries in the table above and do not establish a general-purpose bodybuilding or wellness schedule.
Key Considerations
- DAC changes the duration of exposure; it should not be confused with a no-DAC formulation.
- Growth hormone and IGF-1 changes are biological measures, not proof of improved performance.
- Repeated dosing can produce cumulative effects on IGF-1.
References
05. Ipamorelin (NNC 26-0161) — Research, dosing evidence, and safety
Overview
Ipamorelin (NNC 26-0161) is a growth-hormone secretagogue that acts through the ghrelin receptor. Research has examined growth-hormone release and gastrointestinal applications.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 5 mg | 100–250 mcg | Daily (as listed in source) |
| 10 mg | 100–250 mcg | Daily (as listed in source) |
Research Considerations
- Route of administration and study population affect interpretation of research findings.
- Growth-hormone release does not automatically demonstrate muscle gain or faster recovery.
- Combination protocols with CJC-1295 should not be assumed to have the same evidence as either ingredient alone.
References
06. SS-31 (Elamipretide) — Research, dosing evidence, and safety
Overview
SS-31, also known as elamipretide and previously studied under the code name MTP-131, is a mitochondria-targeting tetrapeptide studied for its interaction with cardiolipin and mitochondrial membrane function.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 10 mg | 5–20 mg | Daily (as listed in source) |
| 30 mg | 5–10 mg | Daily (as listed in source) |
| 50 mg | 5–10 mg | Daily (as listed in source) |
Approved Product Dose and Indication
| Product | Labeled Dose | Population and Indication |
|---|---|---|
| FORZINITY (elamipretide) | 40 mg once daily | Adults and pediatric patients with Barth syndrome weighing at least 30 kg |
| Severe renal impairment in adults, not on dialysis | 20 mg once daily | Formulation-specific dose modification in the product label |
The labeled dose applies to FORZINITY, the regulated elamipretide product. Its approved indication is specific to Barth syndrome. The source-listed research vial amounts above are separate entries and should not be interpreted as FORZINITY dosing instructions.
Research Considerations
- Elamipretide has been studied for its effects on mitochondrial function and cardiolipin interactions.
- Research findings in specific diseases do not establish benefits for general wellness, anti-aging, exercise recovery, or athletic performance.
- Research protocols and regulated product labeling describe different contexts and should be evaluated separately.
References
07. MOTS-C — Research, dosing evidence, and safety
Overview
MOTS-C is a mitochondrial-derived peptide investigated for its role in metabolic regulation, cellular stress responses, and pathways associated with insulin sensitivity.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 5 mg | 500 mcg–2 mg | Daily (as listed in source) |
| 10 mg | 200 mcg–1 mg | Daily (as listed in source) |
| 20 mg | 200 mcg–1 mg | Daily (as listed in source) |
| 40 mg | 200 mcg–1 mg | Daily (as listed in source) |
Research Considerations
- AMPK signaling and glucose metabolism are key research topics.
- Animal findings do not establish human weight-loss, endurance, or longevity benefits.
- Human pharmacokinetics, safety, and an appropriate clinical dose remain insufficiently characterized.
References
08. NAD+ (Nicotinamide Adenine Dinucleotide, Oxidized Form) — Research and evidence
Overview
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular redox reactions, energy metabolism, and several enzymes involved in cellular maintenance. NAD+ is the oxidized form; NADH is its reduced form. NAD+ is not a peptide.
Source-Listed Dosing and Vial Strengths
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 500 mg | 50–100 mg | Daily (as listed in source) |
| 1,000 mg | 50–100 mg | Daily (as listed in source) |
Research Context by Form
| Form | Dosing Reference | Evidence Context |
|---|---|---|
| Oral NAD+ and related precursors | Varies by compound and study | Do not equate NAD+ with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). |
| Intravenous NAD+ | Protocols vary by clinic and formulation | Evidence supporting many wellness claims remains limited. |
| Subcutaneous NAD+ | No standardized general-purpose regimen established | Formulation and route require separate evaluation. |
Research Considerations
- NAD+ biology does not by itself establish that NAD+ administration improves energy, aging, or cognition.
- Research on NR or NMN should not be presented as direct evidence for injected NAD+.
- Administration route, product formulation, and study endpoints matter when interpreting research.
References
09. FOXO4-DRI (FOXO4 D-Retro-Inverso Peptide) — Research, dosing evidence, and safety
Overview
FOXO4-DRI is an experimental D-retro-inverso peptide designed to interfere with interactions between FOXO4 and p53. Research has investigated its potential effects on senescent-cell survival pathways.
Source-Listed Dosing and Vial Strength
| Vial Strength | Source-Listed Amount | Frequency |
|---|---|---|
| 10 mg | 250–500 mcg | Daily (as listed in source) |
Research Evidence
- Foundational research examined cellular systems and aged mice.
- Studies investigated senescent-cell survival pathways and tissue outcomes.
- These findings do not establish a human dose or prove human anti-aging effects.
Handling and Storage Considerations
Storage conditions depend on the specific product, packaging, and manufacturer documentation. Follow validated manufacturer instructions for lyophilized material and any prepared solution. Generic storage recommendations do not establish a validated stability period.
References
10. GLOW (GHK-Cu / BPC-157 / TB-500 Blend) — Research, dosing evidence, and safety
Overview and composition
GLOW is a marketing name commonly used for a combination of GHK-Cu, BPC-157, and TB-500 or thymosin-related material. It is not a single standardized compound and has no separate established scientific or generic drug name. Composition, ingredient identity, and amounts may vary among suppliers. Verify the actual product specification before comparing reported protocols.
Source-listed vial strength and protocol
| Vial strength / formulation | Source-listed amount per administration | Frequency |
|---|---|---|
| 70 mg total blend | 2,330 mcg total blend (2.33 mg) | Daily |
These values reproduce the supplied dosage-chart entry. They are source-listed figures, not a clinically established dosing recommendation for GLOW as a combined formulation. The chart entry does not establish the amount of each ingredient in an individual administration.
Reported example of blend composition
| Component | Reported amount per administration |
|---|---|
| GHK-Cu (copper peptide) | 1.67 mg |
| BPC-157 | 0.33 mg |
| TB-500 / thymosin-related material | 0.33 mg |
| Total | 2.33 mg |
The component amounts above are a reported example and should not be assumed to describe every product sold as GLOW. The combined total is approximately 2.33 mg. Confirm the manufacturer's stated composition and the identity of each ingredient before treating this example as applicable to a particular vial.
Composition and concentration
Blend ratios and total vial strengths can differ. A reported concentration should be checked against the total vial content, each ingredient's stated amount, and the final solution volume. For example, a 70 mg total blend at 23.3 mg/mL corresponds to approximately 3 mL of final solution. This arithmetic alone does not validate the product's identity, preparation, stability, or suitability for any particular use.
Research considerations
- Evidence relating to an individual ingredient does not establish the effectiveness or safety of the combined blend.
- GHK-Cu research involving topical formulations does not establish the effects of injectable use.
- TB-500 is a market name; confirm the exact molecular identity and specification with the manufacturer.
- Blend stability, ingredient compatibility, and sterility require product-specific data.
- The source-listed daily frequency should not be interpreted as a clinically validated regimen for the combined formulation.
References
11. KLOW (GHK-Cu / BPC-157 / TB-500 / KPV Blend) — Research, dosing evidence, and safety
Overview and composition
KLOW is a marketing name for a multi-ingredient blend. Commonly advertised formulations include GHK-Cu, BPC-157, TB-500 or thymosin-related material, and KPV. KLOW is not a single standardized compound and has no separate established scientific or generic drug name. Ingredient identity, ratios, and total vial content may differ among suppliers. Verify the manufacturer's specification for the actual product.
Source-listed vial strength and protocol
| Vial strength / formulation | Source-listed amount per administration | Frequency |
|---|---|---|
| 80 mg total blend | 2–6 mg total blend | Daily |
These figures reproduce the supplied dosage-chart entry. They are source-listed values, not a clinically established dosing recommendation for KLOW as a combined formulation. The listed amount refers to the total blend, not to each ingredient individually.
Composition reference
| Ingredient | Research area |
|---|---|
| GHK-Cu (copper peptide) | Peptide signaling, skin biology, and tissue-related research |
| BPC-157 | Preclinical gastrointestinal and musculoskeletal research |
| TB-500 / thymosin-related material | Identity-dependent tissue-related research |
| KPV | Experimental anti-inflammatory and gastrointestinal research |
Dosing reference
The source-listed entry for KLOW is 2–6 mg of total blend daily for an 80 mg vial. Online schedules may differ in composition, total amount, frequency, and cycle length. Do not assume that this entry applies to a product with different ingredient quantities or ratios. The source-listed schedule does not establish the safety or effectiveness of the combined formulation.
Research considerations
- Individual ingredient studies do not establish the effects or safety of the combined product.
- Product identity, component ratios, and batch consistency are central to interpreting research.
- TB-500 is a market name; confirm the exact molecular identity and manufacturer specification.
- Concentration calculations must use the actual total amount and final solution volume, not a generic KLOW formula.
- Blend stability, compatibility, and sterility require product-specific evidence.
References
12. BPC-157 (Body Protection Compound-157) — Research, dosing evidence, and safety
Overview
BPC-157 is a synthetic 15-amino-acid peptide studied primarily in preclinical gastrointestinal, tendon, ligament, and musculoskeletal injury models. The name is commonly expanded as "Body Protection Compound-157." It does not have an established generic drug name.
Source-listed vial strengths and dosing reference
| Vial strength | Source-listed amount per administration | Frequency |
|---|---|---|
| 5 mg | 200–600 mcg | Daily |
| 10 mg | 200–600 mcg | Daily |
| 20 mg | 200–600 mcg | Daily |
| 40 mg | 200–600 mcg | Daily |
These entries reproduce the supplied dosage-chart values. They are source-listed figures, not a clinically established dosing recommendation. The chart entry does not establish an optimal dose, route, or treatment duration, and the listed amounts should not be interpreted as validated human treatment protocols.
Research evidence
- Animal studies have investigated tendon, ligament, muscle, and gastrointestinal outcomes.
- Mechanistic studies have examined angiogenesis, fibroblast activity, and inflammatory pathways.
- Human evidence remains limited and does not establish an optimal dose, route, or treatment duration.
- Findings from preclinical studies cannot by themselves establish safety or effectiveness in humans.
Handling and product considerations
- Follow the manufacturer's documented storage conditions for the specific formulation.
- Do not assign a universal refrigerated shelf life without formulation-specific stability evidence.
- For injectable products, identity and purity testing are distinct from sterility and endotoxin testing.
- Vial strength alone does not establish product quality, sterility, or suitability for human use.